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Abstract: Thymoquinone (TQ) is the main biologically active constituent of Nigella sativa. Many
studies have confirmed its anticancer actions. Herein, we investigated the different anticancer
activities of, and considered resistance mechanisms to, TQ. MTT and clonogenic data showed TQ’s
ability to suppress breast MDA-MB-468 and T-47D proliferation at lower concentrations compared to
other cancer and non-transformed cell lines tested (GI50 values ≤ 1.5 µM). Flow-cytometric analyses
revealed that TQ consistently induced MDA-MB-468 and T-47D cell-cycle perturbation, specifically
inducing pre-G1 populations. In comparison, less sensitive breast MCF-7 and colon HCT-116 cells
exhibited only transient increases in pre-G1 events. Annexin V/PI staining confirmed apoptosis
induction in MDA-MB-468 and HCT-116 cells, which was continuous in the former and transient in
the latter. Experiments revealed the role of reactive oxygen species (ROS) generation and aneuploidy
induction in MDA-MB-468 cells within the first 24 h of treatment. The ROS-scavenger NAD(P)H
dehydrogenase (quinone 1) (NQO1; DT-diaphorase) and glutathione (GSH) were implicated in
resistance to TQ. Indeed, western blot analyses showed that NQO1 is expressed in all cell lines in this
study, except those most sensitive to TQ-MDA-MB-468 and T-47D. Moreover, TQ treatment increased
NQO1 expression in HCT-116 in a concentration-dependent fashion. Measurement of GSH activity
in MDA-MB-468 and HCT-116 cells found that GSH is similarly active in both cell lines. Furthermore,
GSH depletion rendered these cells more sensitive to TQ’s antiproliferative actions. Therefore, to
bypass putative inactivation of the TQ semiquinone metabolite, the benzylamine analogue was
designed and synthesised following modification of TQ’s carbon-3 atom. However, the structural
modification negatively impacted potency against MDA-MB-468 cells. In conclusion, we disclose the
following: (i) The anticancer activity of TQ may be a consequence of ROS generation and aneuploidy;
(ii) Early GSH depletion could substantially enhance TQ’s anticancer activity; (iii) Benzylamine
substitution at TQ’s carbon-3 failed to enhance anticancer activity.
Keywords: thymoquinone; aneuploidy; apoptosis; ROS generation; GSH depletion
1. Introduction
Thymoquinone (TQ, Figure 1) is the major bioactive phytochemical of the plant
Nigella sativa. Many researchers describe TQ’s ability to inhibit cancer cells’ growth via
targeting signalling pathways that underpin cancer hallmarks [1–3], e.g., proliferative
signalling, growth suppressor evasion, resisting cell death, and metastasis [4]. For instance,
TQ suppresses PI3K/Akt signal transduction in MDA-MB-468 and T-47D breast [5], induces
p53/p21 expression in HCT-116 colon, and induces caspase-dependent apoptosis in A549
lung carcinoma cells [6]; it also inhibits bone metastasis of breast MDA-MB-231 cells [7].
Moreover, TQ can be used as an adjuvant agent that sensitises cancer cells to chemotherapy
by suppressing resistance mechanisms [8,9]. Effenberger et al. (2010) found that TQ
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improved doxorubicin potency against leukaemic HL-60 cells and enhanced sensitivity of
multi-drug resistant MCF cells to topotecan [10].
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blasts) were used as a normal cell line model, revealing a GI50 value of 13.4 µM. DMSO 
vehicle did not affect cancer cell growth (Figure S1). In clonogenic assays, TQ significantly 
suppressed carcinoma cell colony formation (Figure 2B and Figure S2). The average plat-
ing efficiencies were: A549, 30%; HCT-116, 22%; HT-29, 30%; MCF-7, 25%; MDA-MB-468, 
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Figure 1. Thymoquinone Structure.
Reactive oxygen species (ROS) production by natural product or natural product-
deriv d chemotherapy agents (such as doxorubicin) is known to contribute to anticancer
activity [11]. Free radicals are known mediators of DNA damage through oxidising nu-
cleoside bases, leading to cell-cycle arrest, and either repair or apoptosis [12]. TQ acts as
antioxidant (at low concentration) and pro-oxidant (at higher concentration) [13]. Inter-
estingly, TQ can also serve as a pro-oxidant even at low concentrations in the presence of
copper ions, which co-exist at considerably higher levels in various malignancies [13,14].
Indeed, TQ’s cellular oxida ive damage leading to apoptosis is described by other re-
searchers, e.g., in lymphoma [15], colon [16], hepatic [17], ovarian [18], and prostate [19]
carcinoma cells. However, TQ’s oxidative stress can be neutralised by cellular-protective
ROS scavengers: NAD(P)H: quinone oxidoreductase 1 (NQO1) and glutathione (GSH) [20].
For instance, NQO1 confers protection for MCF-7 against TQ’s oxidative stress, and its inhi-
bition by dicoumarol renders MCF-7 cells TQ-sensitive [21]. Furthermore, GSH depletion
enhanced TQ-induced apoptosis in human laryngeal HEp-2 carcinoma cells [22].
Herein, we investigated the activity and resistance mechanisms of carcinoma cells
to TQ. F rst, we confirmed TQ’s ability to inhibit proliferation and induce apoptosis in
carcinoma cells with different sensitivities. We then examined TQ’s ability to induce specific
early cell-cycle perturbations in sensitive cells and possible ROS contribution to these
changes. Thirdly, we interrogated the correlation between ROS scavengers and cancer cells’
sensitiv ty to TQ, and whether GSH depletion cou d modulate th se sensitivities. Gui ed
by ROS-generation and -scavenger results, we synthesised a structural analogue of TQ in
an attempt to bypass resistance mechanisms and determine whether such modification can
enhance its antiproliferative activity compared to TQ.
2. Results
2.1. Thymoquinone Inhibits Growth and Colony Formation of Carcinoma Cells
TQ significantly suppressed the growth and colony-formation of cancer cell lines.
As shown in MTT assays (Figure 2A, Table 1), TQ potently inhibited MDA-MB-468 and
T-47D proliferation, with low GI50 values of ≤1.5 µM. In comparison, TQ’s GI50 values in
A549 and HT-29 were higher, reaching ~19 and ~27 µM, respectively. HCT-116, MCF-7,
and MIAPaCa-2 cells were similarly sensitive to TQ, with GI50 ~ 12 µM. MRC-5 (lung
fibroblasts) were used as a normal cell line model, revealing a GI50 value of 13.4 µM. DMSO
vehicle did not affect cancer cell growth (Figure S1). In clonogenic assays, TQ significantly
suppressed carcinoma cell colony formation (Figure 2B and Figure S2). The average plating
efficiencies were: A549, 30%; HCT-116, 22%; HT-29, 30%; MCF-7, 25%; MDA-MB-468, 20%;
MIAPaCa-2, 30%; and T-47D, 35%. MDA-MB-468 and T-47D cells exhibited the highest
sensitivities to TQ, with significant inhibition of colony formation at ~1 µM, while no
colonies were seen at 5 µM. Other cell lines were less sensitive, and colony formation was
suppressed at concentrations ≥ 5 µM.
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Figure 2. (A). Line graphs show TQ’s growth-inhibitory effects on A549, HCT-116, HT-29, MCF-7, MDA-MB-468, MI-
APaCa-2, T-47D, and MRC-5. Each graph shows three independent MTT trials. For each graph, the T0 value is the average 
of three trials. Cells were seeded in 96-well plates (3 × 103 cells/well) and treated with TQ for 72 h. No. trials ≥3; n = 4 per 
independent experiment. (B). Mean ± SD bars show TQ’s inhibition of A549, HCT 116, HT-29, MCF-7, MDA-MB-468, 
MIAPaCa-2, and T-47D colonies. Data presented as mean survival fraction as % of control. Asterisk indicates significant 
inhibition (p ≤ 0.05). Cells were seeded, treated with TQ (24 h), and then medium was replaced. When colonies contained 
≥50 cells in control wells, colonies were fixed, stained, and counted. Plating efficiencies ranged between 20 and 35%. No. 
trials ≥3; n = 2 per independent trial.  
  
Figure 2. (A). Line graphs show TQ’s growth-inhibitory effects on A549, HCT-116, HT-29, MCF-7, MDA-MB-468,
MIAPaCa-2, T-47D, and MRC-5. Each graph shows three independent MTT trials. For each graph, the T0 value is the
average of three trials. Cells were seeded in 96-well plates (3 × 103 cells/well) and treated with TQ for 72 h. No. trials ≥ 3;
n = 4 per independent experiment. (B). Mean ± SD bars show TQ’s inhibition of A549, HCT 116, HT-29, MCF-7, MDA-
MB-468, MIAPaCa-2, and T-47D colonies. Data presented as mean survival fraction as % of control. Asterisk indicates
significant inhibition (p ≤ 0.05). Cells were seeded, treated with TQ (24 h), and then medium was replaced. When colonies
contained ≥50 cells in control wells, colonies were fixed, stained, and counted. Plating efficiencies ranged between 20 and
35%. No. trials ≥ 3; n = 2 per independent trial.
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Table 1. TQ’s anti-proliferative effects on human carcinoma and fibroblast cell lines.
Cell Line GI50 (µM)
Lung Carcinoma (A549) 18.8 ± 1.9
Colon Carcinoma (HCT-116) 12.7 ± 0.9
Colon Carcinoma (HT-29) 27.3 ± 3.0
Breast Carcinoma (MCF-7) 11.3 ± 1.3
Pancreatic Carcinoma (MIAPaCa-2) 12.6 ± 2.2
Breast Carcinoma (MDA-MB-468) 1.0 ± 0.2
Breast Carcinoma (T-47D) 1.5 ± 0.1
Foetal Lung Fibroblast (MRC-5) 13.4 ± 2.1
GI50 values were estimated from MTT assays following 72 h TQ treatment (n = 4 per trial) and expressed as
mean ± SD from 3 independent trials.
2.2. Thymoquinone Caused Perturbation of Cell-Cycle Progression
To determine whether the antiproliferative action of TQ was a consequence of cell-
cycle perturbations, flow-cytometric cell-cycle analysis was implemented, using PI to stain
the DNA. Four cell lines were selected: the more sensitive being MDA-MB-468 and T-47D
and the less sensitive being MCF-7 and HCT-116. The concentrations used were guided by
MTT and clonogenic assay results: for MDA-MB-468, T-47D: 1, 5, 10 µM; and for MCF-7,
HCT-116: 10, 20 µM. The most significant cell-cycle perturbation seen in MDA-MB-468 and
T-47D cells after TQ exposure was a concentration-dependent increase in pre-G1 events,
indicating apoptosis induction (Figure 3 and Figure S3). MDA-MB-468 showed decreased
events in G1, especially after 72 h exposure to 1 and 5 µM TQ. T-47D exhibited decreased G1
and G2/M events at 5 µM after 72 h. At 10 µM, cells from both cell lines appeared to have
undergone massive apoptosis accompanied by a stark decrease in G1, S, and G2/M events
after 24 and 72 h exposures. MCF-7 cells also exhibited significant concentration-dependent
increases in pre-G1 events accompanied by decreased G1 and S phases, especially following
24 h exposure to 20 µM TQ. After 72 h, MCF-7 populations appeared to have recovered
from TQ-induced perturbation at 10 µM. However, 72 h exposure to 20 µM TQ was still
able to induce significantly increased pre-G1 and decreased G1 and S events, but to a
reduced extent compared to 24 h. Likewise, in HCT-116 cells, 24 h exposure to 20 µM TQ
revealed significant accumulation of pre-G1 events with decreased G1, S, and G2/M events,
while no change was seen with 10 µM TQ. Following 72 h, 10 µM TQ induced significant
G1/S arrest with decreased G2/M events; at 20 µM, the most significant perturbation
(though less than after 24 h treatment) was the accumulation of pre-G1 events (Figure 3
and Figure S4).
2.3. Thymoquinone Induced Apoptosis
To confirm that pre-G1 events detected in cell-cycle analyses were due to apoptosis
induction, annexin V/PI flow-cytometry-based apoptosis assays were carried out in two
selected cell lines: MDA-MB-468 and HCT-116. TQ concentrations adopted were 1, 5, and
10 µM for MDA-MB-468 and 10 and 20 µM for HCT-116 cells. For MDA-MB-468, consistent
with the pre-G1 population, annexin V/PI showed a concentration-dependent increase
in annexin-positive (A+) cells (Figure 4 and Figure S5). Following 24 h treatment, the
majority of apoptotic events detected were in the early-apoptotic quadrant, giving ~15%
for 1 µM, 25% for 5 µM, and 45% for 10 µM TQ. After 72 h, apoptotic events had shifted
to the late-apoptotic quadrant, yielding 11% for 1 µM, 19% for 5 µM, and 72% for 10 µM
TQ. In HCT-116 cells, TQ induced significant concentration-dependent increased apoptosis
following 24 h exposure, with the majority of apoptotic events being in the late-apoptotic
quadrant (A+/PI+), reaching 10% for 10 µM and 23% for 20 µM. However, following 72 h,
reduced and non-significant increases in apoptotic cells were seen in these cells even with
20 µM treatment (Figure 4 and Figure S5). Similarly, fewer pre-G1 events were indicated in
HCT-116 cell-cycle analyses after 72 h compared to 24 h treatment.
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Figure 3. Mean ± SD bars showing % events distribution of MDA-MB-468 T-47D, MCF-7, and HCT-116 cell-cycles after 24, 
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µM TQ. In former cells, TQ induced a significant concentration- and time-dependent increase in pre-G1 (<2N), with de-
creases in other cell-cycle phases. In the latter cells and after 24 h, TQ also induced a significant concentration-dependent 
increase pre-G1 (<2N), but after 72 h, fewer pre-G1 events were seen. Cells were treated, then stained with PI, and ≥20,000 
events/sample were analysed. Asterisks indicate significant (p ≤ 0.05) changes compared to control. No. trials ≥3; n = 2 per 
independent experiment. 
Figure 3. Mean ± SD bars showing % events distribution of MDA-MB-468 T-47D, MCF-7, and HCT-116 cell-cycles after
24, 72 h TQ exposures. MDA-MB-468 and T-47D treated with 1, 5, 10 µM Q, and MCF-7 and HCT-116 treated with 10,
20 µM T . In former cells, TQ induced a significan concentration- and time-dependent i crease in pre-G1 (<2N), with
decreases in other cell-cycle phases. In the latter cells and af er 24 h, TQ also induc d a significant concentration-dependent
increase pre-G1 (<2N), but after 72 h, fewer pre-G1 events were seen. Cells were treated, then stained with PI, and ≥20,000
events/sample were analysed. Asterisks indicate significant (p ≤ 0.05) changes compared to control. No. trials ≥ 3; n = 2
per independent experiment.
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Figure 4. Mean ± SD bars showing annexin V/PI results of MDA-MB-468 and HCT-116 cells treated with TQ for 24, 72 h.
MDA-MB-468 cells were treated with 1, 5, 10 µM TQ, and HCT-116 treated with 10, 20 µM TQ. TQ caused a significant
concentration-dependent increase in apoptotic events. Samples were stained with annexin V/PI, and ≥10,000 events were
detected. The percentage of apoptotic events was equal to the sum of cells undergoing early apoptosis (A+/PI−) plus late
apoptosis (A+/PI+). Asterisks indicate statistically significant (p ≤ 0.05) increments compared to control. No. trials ≥ 3;
n = 2 per independent experiment.
2.4. Thymoquinone Induced Reactive Oxygen Species Generation
Quinones are known ROS inducers, so we hypothesised that TQ can generate ROS,
contributing to apoptosis induction. To test this hypothesis, ROS levels were measured
following 6 and 24 h exposures to TQ (1, 5, 10 µM) in both MDA-MB-468 and T-47D
cells (Figure 5). After 6 h, TQ significantly increased ROS in both cell lines concentration-
dependently. ROS levels reached ~1.2-fold for 1 µM, ~2.0-fold for 5 µM, and ≥4-fold for
10 µM TQ compared to untreated control. Following 24 h, reduced ROS generation was
seen, approaching 1.2- and 1.5-fold of untreated control for 5 and 10 µM TQ, respectively.
However, no increases in ROS levels were seen in 1 µM-treated MDA-MB-468 and T-47D
cells following 24 h.
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The early, significant ROS generation suggested that cancer cell proliferation (cell cy-
cling) may be perturbed as early as within 6 h exposure of MDA-MB-468 cells to TQ. We 
therefore inspected MDA-MB-468 cell-cycle distribution after 6, 12, and 24  h exposure to 
5 µM TQ (Figure 6). After 6 h, cell-cycle histograms indicated that TQ induced significant 
early-onset perturbations including the appearance of aneuploid cells at G1, S, and G2/M 
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accompanied by increased pre-G1 events. After 24  h, the percentage of aneuploid cells 
decreased to lower levels compared to 6 and 12 h treatment groups, while some pre-G1 
Figure 5. Mean ± SD bars showing a significant increase in ROS caused by TQ in MDA-MB-468 and T-47D in a concentration-
dependent fashion. Higher ROS levels were seen in both cells after 6 h TQ treatments (1, 5, 10 µM) compared to the control.
After 24 h, TQ (5, 10 µM) increased ROS but to reduced levels compa ed to 6 h treatments. No. trials ≥ 3; n = 2 per
independent experiment. Asterisk indicates a statistically significant (p ≤ 0.05) fold increase relative to control.
2.5. Thymoquinone Induced Early Temporary Aneuploidy in MDA-MB-468 Cell Cycle
The early, significant ROS generation suggested that cancer cell proliferation (cell cycling)
may be perturbed as early as within 6 h exposure of MDA-MB-468 cells to TQ. We therefore
inspected MDA-MB-468 cell-cycle distribution after 6, 12, and 24 h exposure to 5 µM TQ
(Figure 6). After 6 h, cell-cycle histograms indicated that TQ induced significant early-onset
perturbations including the appearance of aneuploid cells at G1, S, and G2/M phases. Fol-
lowing 12 h, a stark increase in aneuploid cells was seen in all cell-cycle phases, accompanied
by increased pre-G1 events. After 24 h, the percentage of aneuploid cells decreased to lower
levels compared to 6 and 12 h treatment groups, while some pre-G1 events could still be
detected. No aneuploid populations were observed in the untreated samples.
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2.6. Thymoquinone Induced NQO1 in Carcinoma Cells
Cancer cells can exploit ROS scavengers to outmanoeuvre increased ROS levels.
Hence, we hypothesised that TQ-induced ROS triggered expression and/or activity of
ROS scavengers, e.g., NQO1 and GSH. To confirm this hypothesis, NQO1 expression
was investigated by western blot in untreated A549, HCT-116, HT-29, MCF-7, MDA-MB-
468, MIAPaCa-2, and T-47D protein lysates (Figure 7). MDA-MB-468 and T-47D did not
show any detectable NQO1 expression; however, obvious NQO1 bands were detected in
lysates prepared from all other cell lines. Band intensities, determined in arbitrary units
by densitometry/image studio software, are represented graphically in Figure 7. Next,
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time-dependent incr ase i NQO1 was observed in HCT-116, whil o NQO1 exp ssion was se n in
MDA-MB-468 lysates. Assays were rep ated three times. Asterisks indicate a statistically ig ificant
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2.7. Thymoquinone Depleted GSH in HCT-116 and MDA-MB-468
Several quinones are known to deplete cellular GSH [23]; hence, we tested whether
TQ was able to deplete GSH. GSH activity was measured in HCT-116 and MDA-MB-468
following 24 h TQ treatment using 1 and 5 µM (MDA-MB-468) and 10 and 20 µM (HCT-116)
TQ (Figure 9A,B). TQ (5 µM) significantly depleted GSH activity in MDA-MB-468 cells
to ~40% of the control values. TQ (20 µM) decreased GSH activity in HCT-116 to ~50%
of untreated control. However, no significant change in GSH activity was seen using
lower concentrations.
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20 µM, respectively. (C,D): Line graphs showing growth-inhibitory effects of BSO in MDA-MB-468
and HCT-116. Means ± SDs from one representative MTT trial (No. trials ≥ 3; n = 4 per independent
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effects on cell proliferation. Asterisk indicates a statistically significant (p ≤ 0.05).
Molecules 2021, 26, 5136 11 of 20
2.8. GSH Depletion Enhanced Thymoquinone Antiproliferative Activity
GSH (in addition to NQO1) has been implicated in resistance to TQ. Therefore, we
hypothesised that early GSH depletion of carcinoma cells before TQ introduction might
prolong oxidative stress, rendering these cells more sensitive to TQ antiproliferative effects.
To test this hypothesis, we selected buthionine sulfoximine (BSO) as a GSH-depleting
agent. BSO reduces levels of glutathione by inhibiting γ-glutamylcysteine synthetase, the
enzyme required in the first step of glutathione synthesis and being investigated as an
adjunct in cancer treatment, to increase cancer cells’ sensitivity to oxidative stress caused
by chemotherapy [24]. BSO by itself could also affect cell viability. Accordingly, we aimed
to achieve maximum GSH depletion with minimal effect on cell viability. Initially, MTT
assays were conducted to determine the sensitivity of MDA-MB-468 and HCT-116 to BSO
alone (Figure 9C,D). Guided by MTT results, cells were incubated with BSO for 24 h at
concentrations 10, 20, 100, and 200 µM, and GSH activity was measured (Figure 9E,F).
In conclusion, concentrations of 10 and 200 µM BSO were selected to deplete GSH in
MDA-MB-468 and HCT-116, respectively, before TQ introduction. These concentrations
similarly depleted GSH activity by ~88% of the values obtained from untreated controls
(i.e., GSH activity is depleted to ~12% of its control values) in both MDA-MB-468 and
HCT-116 without, or minimally, affecting cell viability. Then, a modified MTT assay was
performed adopting BSO concentrations that depleted GSH but did not affect MDA-MB-
468 or HCT-116 cell growth and viability, in which cells were pre-incubated with BSO.
After 24 h, TQ was introduced, and cells were incubated for an additional 72 h. Cell growth
and viability were determined by MTT assays. Concurrently, a similar experimental set
for each cell line was established where cells were treated with TQ only, without BSO
pre-treatment and continuous incubation. Figure 10 and Figure S6 demonstrate that GSH-
depleted cells exhibited greater sensitivity to TQ than non-GSH-depleted cells. TQ GI50
in HCT-116 decreased significantly from ~13.0 µM to ~3.5 µM in GSH-depleted cells. In
MDA-MB-468, TQ GI50 slightly but not significantly decreased following GSH depletion
from 1.0 to 0.8 µM.
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2.9. Synthesis of Thymoquinone Analogue (TQ1) Could Bypass GSH Inactivation
GSH is known to reduce (and inactivate) TQ into glutathionyldihydro-TQ by a non-
enzymatic rea tion th t involves one-step, two-electron transfer (Michael addition). GSH
depletion could increase (HCT-116) cancer cells’ sensitivity to TQ. Hence, we sought to
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synthesise a TQ analogue (TQ1) that can bypass TQ inactivation by GSH. Benzylamine
was used as a source of nucleophilic nitrogen that can attack carbon 3 of TQ (Figure 11).
The TQ1 structure ((3-(benzylamino)-5-isopropyl-2-methylcyclohexa-2,5-diene-1,4-dione) was
confirmed using 1-dimensional 1H NMR spectroscopy (400 MHZ, chloroform-d) (Figure S7).
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Figure 11. Synthesis of TQ1 (c) by Michael addition reaction of benzylamine (b) and TQ (a) with the less nucleophilic
nitrogen attacking carbon 3 of TQ.
2.10. TQ1 Displayed Decreased Growth-Inhibitory Actions Compared to Thymoquinone
TQ1 antiproliferative activity as tested in both MDA-MB-468 and HCT-116 cells sing
the MTT assay (Figure 12). Conversely to our hypothesis, TQ1 was significantly (p ≤ 0.05) less
potent as a growth-inhibitory agent compared to TQ in MDA-MB-468, as its GI50 increased to
13.5 ± 2.7 µM. However, TQ1’s GI50 was comparable to TQ in HCT-116 (14.4 ± 1.5 µM).
Molecules 2021, 26, x FOR PEER REVIEW 12 of 20 
 
 
synthesise a TQ analogue (TQ1) that can bypass TQ inactivation by GSH. Benzylamine 
was used as a source of nucleophilic nitrogen that can attack carbon 3 of TQ (Figure 11). 
The TQ1 structure ((3-(benzylamino)-5-isopropyl-2-methylcyclohexa-2,5-diene-1,4-dione) 
was confirmed using 1-dimensional 1H NMR spectroscopy (400 MHZ, chloroform-d) (Fig-
ure S7).  
 
Figure 11. Synthesis of TQ1 (c) by Michael addition reaction of benzylamine (b) and TQ (a) with the less nucleophilic 
nitrogen attacking carbon 3 of TQ. 
2.10. TQ1 Displayed Decreased Growth-Inhibitory Actions Compared to Thymoquinone 
TQ1 antiproliferative activity was tested in both MDA-MB-468 and HCT-116 cells 
using the MTT assay (Figure 12). Conversely to our hypothesis, TQ1 was significantly (p  
≤  0.05) less potent as a growth-inhibitory agent compared to TQ in MDA-MB-468, as its 
GI50 increased to 13.5 ± 2.7 µM. However, TQ1’s GI50 was comparable to TQ in HCT-116 
(14.4 ± 1.5 µM). 
 
Figure 12. Growth-inhibitory effects of TQ1 in MDA-MB-468 and HCT-116. Each representative graph shows one inde-
pendent MTT trial. Cells were seeded in 96-well plates (3 × 103 cells/well) and treated with TQ1 for 72 h. No. trials ≥3; n = 
4 per independent experiment. 
3. Discussion 
TQ is the main biologically active constituent of Nigella sativa; many researchers have 
described TQ’s ability to inhibit the growth of cancer cells [4]. In this work, we investi-
gated the resistance mechanisms of cancer cells to TQ. Initially, TQ’s growth-inhibitory 
activity was tested using MTT assays against a panel of human-derived carcinoma cells 
from the breast, colon, lung, and pancreas (Figure 2A, Table 1). MDA-MB-468 and T-47D 
Figure 12. Growth-inhibitory effects of TQ1 in MDA-MB-468 and HCT-116. Each representative graph shows one indepen-
dent MTT trial. Cells were seeded in 96-well plates (3 × 103 cells/well) and treated with TQ1 for 72 h. No. trials ≥ 3; n = 4
per independent experiment.
3. Discussion
TQ is the main biologically active constituent of Nigella sativa; many researchers have
described TQ’s ability to inhibit the growth of cancer cells [4]. In this work, we investigated
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the resistance mechanisms of cancer cells to TQ. Initially, TQ’s growth-inhibitory activity
was tested using MTT assays against a panel of human-derived carcinoma cells from
the breast, colon, lung, and pancreas (Figure 2A, Table 1). MDA-MB-468 and T-47D
were the most sensitive to TQ’s anti-proliferative actions compared to other cell lines
(A549, HCT-116, HT-29, MCF-7, MIAPaCa-2). Moreover, MDA-MB-468 and T-47D were
~10-fold more sensitive than our normal cell line model (MRC-5 fibroblasts); hence, TQ
exhibited selectivity. The sensitivity of MDA-MB-468 and T-47D to TQ is concordant
with previous studies [5,21]. Additionally, TQ efficiently suppressed MDA-MB-468 and
T-47D colony-forming ability (Figure 2B). Accordingly, individual cells were unable to
resist TQ’s cytotoxic effects and either failed to survive and/or proliferate to form progeny
colonies, after just 24 h exposure. Conversely, clonogenic assays (corroborating MTT data)
revealed that other carcinoma cell lines—A549, HCT-116, HT-29, MCF-7, and MIAPaCa-
2—demonstrated greater resistance to TQ. Thus, these cells survived short-term exposure
and recovered proliferative capacity to form colonies at 1 µM TQ, but they failed to do so
at 5 and 10 µM. Notably, colony formation in the more TQ-resistant cells was thwarted at
lower concentrations compared to growth inhibition detected in MTT assays, indicating
the cytotoxic (rather than cytostatic) potential of TQ. Nevertheless, MTT and clonogenic
assays concur to indicate that MDA-MB-468 and T-47D proliferation and viability were
significantly compromised by TQ at lower concentrations compared to other cell lines.
Flow-cytometric analyses allowed the detection of cell-cycle perturbations induced
by TQ. Upon intercalating DNA, PI becomes potently fluorescent, allowing quantification
of fluorescently stained cellular DNA content. The evolution of sub-diploid pre-G1 (<2N-
DNA) events, especially in MDA-MB-468 and T-47D populations (but also HCT-116 and
MCF-7), indicated apoptosis induction. As a result, the % events in other cycle phases
substantially decreased, especially at 10 µM TQ for MDA-MB-468 and T-47D, and 20 µM
TQ for HCT-116 and MCF-7 cells. Higher TQ concentrations were required to achieve equal
perturbations in MCF-7 and HCT-116 cell cycles. Intriguingly, recovery from TQ’s actions
was apparent following longer incubation (72 h), evidenced by decreased sub-diploid
populations and reduced changes in G1, S, and G2/M events. The recovery of MCF-7 and
HCT-116 cells could be a consequence of TQ-inactivation (or the emergence of resistance to
TQ). Furthermore, annexin V-FITC/PI studies of MDA-MB-468 and HCT-116 confirmed
apoptosis induction (Figure 4). MDA-MB-468 showed concentration-dependent increases
in early-apoptotic populations. Membrane asymmetry of these cells is lost, exposing
phosphatidylserine (PS) to the outer membrane surface (an early-apoptotic process); PS
consequently binds to Annexin V-FITC. With prolonged exposure, most apoptotic events
shifted into the late-apoptotic quadrant. These findings indicate that the membrane in-
tegrity of these cells was lost, exposing DNA (a late event in the apoptosis pathway) and
allowing intercalation by PI. HCT-116 also displayed increased apoptotic events but to a
reduced extent. Interestingly, there were more late-apoptotic than early-apoptotic cells;
after 72 h, no further apoptotic events were observed. Hence, TQ initially induced transient
irreparable damage earlier (within 24 h) in HCT-116 cells before its actions were neutralized,
hindering apoptosis, possibly by the emergence or activation of resistance mechanisms.
Many quinones are known to increase ROS production, an apoptosis-inducing an-
ticancer mechanism [23]. In this study, we confirmed TQ’s ability to generate ROS (in
a concentration-dependent fashion) as an early event in MDA-MB-468 and T-47D cells.
However, ROS levels declined or returned to normal following 24 h treatment. ROS
production could be responsible for, or contribute to, TQ’s apoptotic properties, as has
been reported for many natural-product-derived anticancer agents [25]. One mechanism
through which ROS could contribute to apoptosis is via causing irreparable DNA damage,
leading ultimately to mitotic catastrophe. If cells bypassed apoptosis through activating
cell-cycle checkpoints, they would favour asymmetric division (aneuploidy) [26]. Indeed,
we observed that TQ caused early aneuploidy in MDA-MB-468 cells in a similar time
frame to that of ROS generation (6 h, 12 h). Moreover, the % of aneuploid cells declined
as ROS levels decreased after 24 h. Aneuploid cells are the main consequence of mitotic
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slippage; i.e., these cells escape cytokinesis, re-enter into another cycle, and then either
pass directly into apoptosis or continue another division round. On the other hand, the
emergence of aneuploid cells after mitotic slippage might render these cells more resis-
tant to anticancer agents [27]. Resistance to oxidative stress is conferred by the enzyme
NQO1, which catalyses quinones reduction into hydroquinones and the ROS-scavenger
GSH. These proteins allow cancer cells to outmanoeuvre increased ROS and can ultimately
reduce the potency of ROS-inducing anticancer agents. We found that NQO1 is actively
expressed in cell lines with decreased sensitivity to TQ (A549, HCT-116, HT-29, MCF-7, and
MIAPaCa-2, as confirmed by MTT and clonogenic assays). NQO1 can allow these cells to
neutralize TQ-induced oxidative stress and survive. However, sensitive MDA-MB-468 and
T-47D (which showed increased ROS with TQ) do not express NQO1. Furthermore, we saw
that HCT-116 cells upregulate NQO1 expression when treated with TQ, while no NQO1
expression was seen in TQ-treated MDA-MB-468. Interestingly, NQO1 is a known stabilizer
of wild-type (but not mutant) p53 in many carcinoma cells, including HCT-116 [28–30]; in
these cells, NQO1 confers a level of protection against (resistance to) TQ. In MDA-MB-468,
the absence of NQO1, consistent with other studies that failed to detect its expression in
these cells [21,31], may underlie the enhanced sensitivity to TQ shown by MDA-MB-468
cells. Interestingly, and consistent with our observations, Kalo E et al. (2012) reported
that carcinoma cells expressing mutant-p53 (such as MDA-MB-468) failed to induce NQO1
expression in response to oxidative stress [32]. Hence, one would expect to see increased
ROS in MDA-MB-468 (due to delayed ROS neutralisation). However, the ROS-scavenger
GSH might negatively impact TQ’s activity in these cells. Indeed, we found that GSH is
active in both untreated MDA-MB-468 and HCT-116 cells, and its activity is not affected
when cells are treated with TQ at concentrations of 1 and 10 µM, respectively (Figure 9).
However, significant decreases in GSH activity were seen in MDA-MB-468 using 5 µM
and HCT-116 using 20 µM TQ. It was noted that lower BSO concentrations are required
to supress GSH in MDA-MB-468 compared to HCT-116 cells. In fact, mutant-p53 was
shown to diminish glutathione synthesis via supressing an important GSH-ROS system’s
controller gene namely SLC7A11, rendering mutant-p53 tumours susceptible to oxida-
tive damage [33,34]. In conclusion, both NQO1 and GSH conferred protection against
TQ-induced ROS in HCT-116, and possibly other less sensitive cell lines. Alternatively,
MDA-MB-468 cells appear to rely mainly on GSH for protection against ROS. NQO1 and
GSH (in addition to their ROS-neutralizing actions) contribute to TQ oxido-reduction cy-
cling [20]. They can reverse the pro-oxidant action of TQ’s semiquinone radicals (produced
by its one-step one-electron reduction). NQO1 and GSH can convert TQ directly into
antioxidants (thymohydroquinone and glutathionyldihydro-TQ, respectively) by one-step
two-electron reduction (Figure 13) [20]. Since TQ can deplete GSH and block its conver-
sion into glutathionyldihydro-TQ, one might expect increased semiquinone production.
Semiquinone production is enhanced by three enzymes: NADPH CYP reductase (E1),
NADH CYP-b5 reductase (E2), and NADH ubiquinone oxidoreductase (E3). Semiquinone
radicals (upon undergoing another one-step one-electron reduction) can further enhance
oxidative stress by generating superoxide radicals. Moreover, semiquinone radicals (alone)
have been shown recently to strongly intercalate DNA and may result in DNA strand
breaks and interruption of DNA replication [35].
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Figure 13. Diagram showing TQ’s oxido-reduction cycling. TQ can be converted through enzy-
matic reaction into thymohydroquinone either by a one-step two-electron reduction or by two-step
one-electron reduction. A one-step two-electron reduction can lead to the direct formation of thymo-
hydroquinone by NQO1. TQ may also be reduced in a non-enzymatic reaction through interaction
with GSH to generate glutathionyldihydro-TQ. Alternatively, in one-electron reduction, E1, E2, and
E3 catalyse TQ’s conversion into the pro-oxidant semiquinone. Thereafter, semiquinone is converted
into thymohydroquinone. While thymohydroquinone and glutathionyldihydro-TQ are antioxidants,
semiquinone acts as a pro-oxidant in the tumour environment. The sup rox de a i n produced
by the oxidation of reduced TQ can be detoxified by E4 and E5. In the absence of detoxifying
enzymes, which is common in numerous cancers, the increased superoxide levels can contribute to
the pro-oxidant effect of TQ [20].
Therefore, in this study, we used BSO to deplete GSH. BSO inhibits γ-glutamylcysteine
synthetase, the enzyme required for glutathione synthesis. We found that GSH depletion
significantly (p-value < 0.05) enhanced TQ’s activity in HCT-116 (~4-fold), while less en-
hancement is seen in MDA-MB-468 (~1.3-fold) compared to näive cells. These results
highlight the importance of GSH depletion as a rationale to improve TQ’s actions. Inter-
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estingly, one study showed that GSH depletion by BSO could simultaneously increase
NQO1 expression in vitro [36]. This means that GSH-depleting combination therapy could
synergize with TQ even in cells possessing increased NQO1 expression. Consequently,
we attempted to modify the TQ structure to test the hypothesis that the Michael addition
(the one-step two-electron reduction reaction between TQ and GSH) could be bypassed.
According to our hypothesis, TQ reduction would shift to a one-step one-electron reaction
and produce more semiquinone radicals. GSH is a strong nucleophile (Michael-donor),
with the –SH group responsible for its nucleophilicity. The –SH can attack carbon-3 of TQ
(Michael-acceptor), leading to the production of glutathionyldihydro-TQ (Figure S8). To
prevent the strong nucleophilic attack of GSH, we used the less nucleophilic nitrogen (as a
Michael-donor) of benzylamine, which can similarly attack carbon-3 of TQ. The resulting
analogue was termed TQ1 (3-(benzylamino)-5-isopropyl-2-methylcyclohexa-2,5-diene-1,4-
dione) (Figure 11). In disagreement with our hypothesis, TQ1’s activity was significantly
(p ≤ 0.05) less potent against MDA-MB-468 cells compared to TQ; however, HCT-116
cells retained similar sensitivity to TQ1 as to TQ. A possible explanation could be that
the enzymes E1, E2, and E3 (Figure 13) failed to convert TQ1 into semiquinone radicals
and produce ROS that we suggested were responsible for TQ-induced aneuploidy and
apoptosis. Such failure could be derived from the importance of TQ’s carbon-3, which
seems to be essential for TQ’s conversion to a semiquinone.
In conclusion, we have demonstrated that ROS generation, aneuploidy, and cell-cycle
perturbation are early events triggered by TQ that may contribute to this natural product’s
anticancer activity. We confirm that NQO1 expression and GSH activity confer protection
against TQ activity, but analogue TQ1, designed to thwart resistance mechanisms, failed to
enhance the activity of TQ.
4. Materials and Methods
4.1. Cell Culture
All cell lines were procured from American Type Culture Collection (ATCC), grown
and maintained in RPMI-1640 medium supplemented with 10% foetal bovine serum (FBS).
Cells were subcultured twice a week to sustain logarithmic growth and incubated in a
humidified atmosphere containing 5% CO2 at 37 ◦C. After ≤30 passages and to reduce
phenotypic-genotypic drift, new lower passages were reintroduced from cell stocks that
were cryopreserved at −180 ◦C. TQ (Sigma-Aldrich, Gillingham, UK) top stocks were kept
frozen at −80 ◦C as 20 mM/10 µL aliquots in DMSO (Sigma-Aldrich, Gillingham, UK),
which were thawed promptly before use.
4.2. MTT Assay
Cell viability was determined using an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide, Alfa-Aesar, Lancashire, UK) colourimetric assay. Briefly,
cells were seeded into 96-well plates (3 × 103 cells/well) and allowed to attach overnight
before TQ introduction. Serial dilutions (0.02 µM–200 µM, n ≥ 4) were freshly prepared in
a culture medium. Cell viability was measured twice (at the time of treatment introduction
and after 72 h) by MTT addition. Plates were then incubated for 3 h, allowing metabolic
reduction of yellow MTT into insoluble purple formazan crystals, which were solubilised
in 150 µL DMSO after the supernatants’ aspiration. Data were collected at absorbance
570 nm in a plate reader (PerkinElmer Life and Analytical Sciences, Buckinghamshire,
UK). TQ concentrations required to inhibit growth by 50% (GI50) were calculated using
non-linear regression analysis.
4.3. Clonogenic Assay
Clonogenic assays were used to assess single cells’ ability to survive, proliferate, and
form colonies following brief exposure to TQ. Cells (400/well) were seeded into 6-well
plates in a 2 mL medium. After 24 h incubation, TQ was introduced (1, 5, and 10 µM),
while medium alone was added to controls. Following 24 h treatment, medium containing
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TQ was gently aspirated, cells were washed (2× sterile PBS, 37 ◦C) before fresh TQ-free
medium was introduced, and plates were re-incubated for 7–9 days. The experiment was
concluded when cells in control wells had formed colonies consisting of >50 cells. Wells
were washed with PBS, fixed with methanol (100%; 15 min), stained with methylene blue
(0.5%; 15 min), washed (dH2O), and air-dried, and stained colonies were then counted.
4.4. Cell-Cycle Analysis
The method used is adapted from that described by Nicoletti et al. (1991) [37]. Cells were
seeded and allowed to attach overnight in 6-well plates (1.0 × 105 and 0.5 × 105 cells/well for
24 h and 72 h exposures, respectively). Following treatment, floating cells were collected,
attached cells were trypsinised, and cells were pooled together in FACS tubes. Samples
were washed (PBS; 4 ◦C) before being pelleted by centrifugation (1200 rpm; 5 min; 4 ◦C).
Cells were re-suspended in fluorochrome solution (50 µg/mL PI, 100 µg/mL ribonuclease-
A, 0.1% triton-X-100, 0.1% sodium citrate). Cell-cycle analyses were performed using
an FC-500 Beckham-Coulter flow cytometer. Data were analysed using FlowJo software
(version 10, OR, USA).
4.5. Annexin-V/PI Apoptosis Assay
Cells were seeded at densities of 0.5–0.75 × 105 per well in a 6-well plate, incubated
overnight, and treated the following day. After 24 h and 72 h, cells were harvested,
washed (PBS; 4 ◦C), and transferred with medium containing detached cells into FACS
tubes. After centrifugation (1200 rpm; 5 min; 4 ◦C) and aspiration of supernatants, cells
were re-suspended in 5 µL annexin-V-FITC plus 100 µL 1× annexin-V binding buffer
(BD Pharmingen). Samples were briefly vortexed and incubated (protected from light for
15 min, 25 ◦C). PI (10 µL) plus 400 µL annexin-V binding buffer were added into each
FACS tube followed by incubation for 10 min in the dark at 4 ◦C. Samples were analysed
using Beckman Coulter FC-500 flow cytometer and EXPO32 software, and percentages of
early-apoptotic (annexin-V positive (A+), PI negative (PI−)) and late-apoptotic cells (A+,
PI+) were recorded.
4.6. Western Blotting
Following designated treatments, cells were collected and lysed using NP-40 lysis
buffer containing protease and phosphatase inhibitors. Protein concentrations were mea-
sured using the Bradford assay [38]. Samples were then loaded (50 µg protein each) and
proteins were separated using sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE). By immunoblotting, proteins were transferred onto nitrocellulose membrane,
probed against primary antibody (dilution 1:1000), and thereafter against secondary anti-
body (dilution 1:4000). Protein bands were detected using enhanced chemiluminescence
(Amersham ECL Prime (Buckinghamshire, UK) and LI-COR Biosciences Ltd. C-DiGit® Blot
Scanner, Cambridgeshire, UK). Densitometric analyses of western blots were performed
using Image Studio. Primary antibodies were procured from CST (London, UK): NQO1
and β-Actin. A secondary anti-mouse IgG/HRP antibody was purchased from Dako
(Cambridgeshire, UK).
4.7. Reactive Oxygen Species Assay
To measure ROS production, the ROS-Glo H2O2 (Promega, Madison, WI, USA) assay
was conducted according to the manufacturer’s protocol, which measures the most stable
ROS-H2O2 level. Cells were plated at a density of 5 × 103/70 µL medium in white-walled
opaque bottom 96-well plates and incubated overnight (37 ◦C, 5% CO2). TQ or medium
(10 µL) was added to treated or control wells, respectively, for an extra 6 h and 24 h. Then,
20 µL H2O2 substrate was added to each well either simultaneously with TQ in the 6 h
group or after 18 h in the 24 h group. Finally, 100 µL ROS-Glo solution was added to each
well, and after 20 min, relative luminescence was measured in a plate reader (PerkinElmer
Life and Analytical Sciences, Buckinghamshire, UK).
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4.8. GSH Activity Assay
To measure GSH, the GSH-Glo Glutathione Assay (Promega) assay was conducted
according to the manufacturer’s protocol. Cells were plated at a density of 5 × 103/180 µL
medium in white-walled opaque bottom 96-well plates and incubated overnight (37 ◦C,
5% CO2). TQ or BSO (Sigma-Aldrich, Gillingham, UK) was introduced using designated
concentrations for another 24 h. The medium was aspirated, and a freshly prepared 1× GSH-
Glo reagent (containing luciferin-NT, glutathione S-transferase and reaction buffer) was added.
Samples were mixed briefly in a shaker and incubated (30 min; 25 ◦C). Reconstituted luciferin
detection reagent was added for another 15 min before measuring relative luminescence.
4.9. Synthesis of TQ1
To a stirred solution of TQ (50 mg, 0.3 mmol) in MeOH (5 mL), benzylamine (30 µL,
30 mmol) was introduced by dropwise addition. Following 72 h, the reaction mixture was
concentrated onto silica gel and purified via flash column chromatography (silica gel), eluting
with petroleum ether (40–60) and 20% ethyl acetate to produce a purple solid (40 mg, 54%).
TQ1 structure was confirmed by nuclear magnetic resonance 1H-NMR spectra.
4.10. Statistical Analysis
Experiments were repeated at least three times, and representative experiments are
shown (unless otherwise stated). Data are presented as mean ± SD (or SEM). Statistical
differences between study groups were analysed using two-way ANOVA (unless otherwise
stated). Dunnett’s multiple comparisons were implicated to test significance, determined
as p-value < 0.05.
5. Conclusions
We confirmed TQ’s ability to inhibit the growth and clonogenic capacity of carcinoma
cells, particularly breast MDA-MB-468 (triple-negative) and T-47D (oestrogen receptor-
positive) cells. More importantly, we disclose in this study the following: (i) TQ induces
aneuploidy in MDA-MB-468 cells promptly with ROS production; (ii) Lysates prepared
from less sensitive cell lines (A549, HCT-116, HT-29 and MIAPaCa-2) expressed NQO1.
HCT-116 also exhibited evident GSH activity, and prior GSH depletion significantly en-
hanced TQ’s anticancer activities in these cells even in the presence of NQO1; (iii) Modifying
TQ at the carbon-3 position failed to enhance anticancer activity. Indeed, TQ and TQ1 are
equiactive in HCT-116 cells, while the putative step in MDA-MB-468 cells that renders
them more sensitive to TQ was lost and/or inhibited following structural modification. To
our knowledge, this is the first work investigating changes in both NQO1 expression and
GSH activity in two carcinoma cell lines following treatment with TQ.
Supplementary Materials: The following are available online. Figure S1: DMSO MTT, Figure S2:
Clonogenic photos, Figures S3 and S4: Cell-cycle histograms, Figure S5: Annexin V/PI dot plots,
Figure S6: MTT GSH depleted and non-GSH depleted cells, Figure S7: 1H NMR spectrum of TQ1,
Figure S8: GSH and TQ reaction.
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